In an effort to improve delivery of costly medical treatments, a team of researchers in electrical engineering at the University of Wisconsin–Madison has developed a stimulating method that could make the human body more receptive to certain gene therapies.
8 takeaways from Biogen’s Q1 update: A ‘difficult’ launch for Leqembi, a $103M voucher and a focus on new licensing deals
Biogen’s leaders defended their Eisai-partnered Leqembi during a first-quarter earnings update on Wednesday, saying the Alzheimer’s treatment is on a path to greater uptake as
April 25, 2024